Clinical Trial Update: Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years. [Phase 3]

View source ↗

Summary

Phase 3 trial update reporting safety and immunogenicity results for two doses of the Novartis meningococcal B recombinant vaccine in adolescents aged 11-17; re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• Novartis Meningococcal Serogroup B Recombinant Vaccine (Meningococcal serogroup B recombinant vaccine)

Snippet

Sponsor: Novartis Vaccines | Conditions: Meningococcal Disease | Phase 3 | Status: COMPLETED | Results posted: 2015-03-06